Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markolf Hanefeld

Showing results (101-110 of 121) with videos related to

Pageof 13
Sort By:
Diabetes Care|August 17, 2016
Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized TrialJulio Rosenstock, Ronnie Aronson, George Grunberger, et al.
Diabetologia|September 8, 2021
Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkersFrank Pistrosch, Jan B Matschke, Dorothea Schipp, et al.
The Journal of Clinical Endocrinology and Metabolism|December 25, 2008
The Finnish Diabetes Risk Score is associated with insulin resistance and progression towards type 2 diabetesPeter E H Schwarz, Jiang Li, Manja Reimann, et al.
Folia Medica|May 15, 2009
Pulse pressure is a strong predictor of cardiovascular risk: Data of the risk factors in impaired glucose tolerance for atherosclerosis and diabetes and the Sofia Metabolic Syndrome studiesTheodora S Temelkova-Kurktschiev, Dimo P Kurktschiev, Lyudmila G Vladimirova-Kitova, et al.
European Heart Journal|February 2, 2010
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trialMichel Komajda, John J V McMurray, Henning Beck-Nielsen, et al.
Lancet (London, England)|June 9, 2009
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trialPhilip D Home, Stuart J Pocock, Henning Beck-Nielsen, et al.
Diabetes Care|March 12, 2008
Evaluation of a diabetes management system based on practice guidelines, integrated care, and continuous quality management in a Federal State of Germany: a population-based approach to health care researchUlrike Rothe, Gabriele Müller, Peter E H Schwarz, et al.
Diabetes Care|May 26, 2016
Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 TrialJulio Rosenstock, Bruno Guerci, Markolf Hanefeld, et al.
Cardiovascular Diabetology|March 19, 2013
Structured health care for subjects with diabetic foot ulcers results in a reduction of major amputation ratesMatthias Weck, Torsten Slesaczeck, Hartmut Paetzold, et al.
Plos Genetics|August 8, 2009
Identification of the UBP1 locus as a critical blood pressure determinant using a combination of mouse and human geneticsHana Koutnikova, Markku Laakso, Lu Lu, et al.
Pageof 13

Showing results (101-110 of 121) with videos related to

Sort By:
Pageof 13
Diabetes Care|August 17, 2016
Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized TrialJulio Rosenstock, Ronnie Aronson, George Grunberger, et al.
Diabetologia|September 8, 2021
Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkersFrank Pistrosch, Jan B Matschke, Dorothea Schipp, et al.
The Journal of Clinical Endocrinology and Metabolism|December 25, 2008
The Finnish Diabetes Risk Score is associated with insulin resistance and progression towards type 2 diabetesPeter E H Schwarz, Jiang Li, Manja Reimann, et al.
Folia Medica|May 15, 2009
Pulse pressure is a strong predictor of cardiovascular risk: Data of the risk factors in impaired glucose tolerance for atherosclerosis and diabetes and the Sofia Metabolic Syndrome studiesTheodora S Temelkova-Kurktschiev, Dimo P Kurktschiev, Lyudmila G Vladimirova-Kitova, et al.
European Heart Journal|February 2, 2010
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trialMichel Komajda, John J V McMurray, Henning Beck-Nielsen, et al.
Lancet (London, England)|June 9, 2009
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trialPhilip D Home, Stuart J Pocock, Henning Beck-Nielsen, et al.
Diabetes Care|March 12, 2008
Evaluation of a diabetes management system based on practice guidelines, integrated care, and continuous quality management in a Federal State of Germany: a population-based approach to health care researchUlrike Rothe, Gabriele Müller, Peter E H Schwarz, et al.
Diabetes Care|May 26, 2016
Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 TrialJulio Rosenstock, Bruno Guerci, Markolf Hanefeld, et al.
Cardiovascular Diabetology|March 19, 2013
Structured health care for subjects with diabetic foot ulcers results in a reduction of major amputation ratesMatthias Weck, Torsten Slesaczeck, Hartmut Paetzold, et al.
Plos Genetics|August 8, 2009
Identification of the UBP1 locus as a critical blood pressure determinant using a combination of mouse and human geneticsHana Koutnikova, Markku Laakso, Lu Lu, et al.
Pageof 13